FDA approves first oral treatment for postpartum depression
Following the approval, Biogen plans for the commercial launch Zurzuvae (zuranolone) in Q4 2023.
08 August 2023
08 August 2023
Following the approval, Biogen plans for the commercial launch Zurzuvae (zuranolone) in Q4 2023.
A new FDA guideline gives manufacturers suggestions to identify carcinogenic drug compounds through clinical study.
Ginkgo will receive payments totalling $490m from Merck.
BioNTech will hold marketing global rights for Duality Bio’s antibody-drug conjugates, except in China, Hong Kong, and Macau.
The boards of directors of Danam and Artemis granted unanimous approval for the deal.
Glecirasib received the designation based on results from a pivotal study that assessed its safety and efficacy.
HuidaGene claims its gene therapy candidate was superior to FDA-approved Luxturna in preclinical studies.
Ahead of Eli Lilly's Q2 results, which will likely touch on the company's plans for obesity drugs, we take a look at the ongoing discourse on this drug class.
We will be launching our new event Clinical Trials In Rare Diseases Conference 2023 at Princeton Marriott at Forrestal, New Jersey, USA on 13th-14th September! Bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions and much more. With over 40 solution providers this will be a perfect platform to reconnect with current business partners, meet new vendors and discover which new technologies are being employed to improve your Rare Disease clinical trials.
The COVID-19 pandemic pushed the healthcare industry to rapid digitalization. Increased use of telehealth, telepresence systems, remote diagnostics, predictive AI, and wearable technology is changing how healthcare is delivered and improving patient outcomes. Emerging technologies such as AR and VR are becoming increasingly routine for professional training, surgical assistance, and treatment of psychological and neurological disorders. In the pharma and medical devices industries, AR, VR, and AI are rapidly accelerating drug discovery and manufacturing and generating supply chain efficiencies. New digital opportunities will look to build upon disruptive technologies. However, affordability is a limiting factor to widespread adoption. Per GlobalData estimates, the metaverse market is expected to grow at a CAGR of more than 33% between 2023 and 2030. Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
Give your business an edge with our leading industry insights.